Skip to Content
Merck
All Photos(1)

Key Documents

AB5038P

Sigma-Aldrich

Anti-Synuclein α Antibody

Chemicon®, from rabbit

Synonym(s):

Anti-NACP, Anti-PARK4, Anti-PD1

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

Pricing and availability is not currently available.

biological source

rabbit

Quality Level

antibody form

affinity purified immunoglobulin

antibody product type

primary antibodies

clone

polyclonal

purified by

affinity chromatography

species reactivity

rat, human

manufacturer/tradename

Chemicon®

technique(s)

immunohistochemistry: suitable (paraffin)
western blot: suitable

NCBI accession no.

General description

alpha -Synuclein is a small (140-amino acid) cytoplasmic protein of unclear function that is enriched in presynaptic terminals and is the precursor protein of a nonamyloid beta component of senile plaques in Alzeheimer′s Disease (AD). alpha -Synuclein is located predominantly in the presynaptic nerve terminals in the brain but is also found in low concentrations in all tissues except liver. Recent studies have shown that abnormal aggregation and accumulation of synaptic proteins, including alpha-Synuclein might be associated with plaque formation in AD and seems to be a major component of Lewy bodies in dementia with Lewy bodies (DLB). It has also been identified in the Glial Cytoplasmic Inclusions (GCIs) found in Multiple System Atrophy (MSA).

Specificity

Recognizes Alpha-synuclein. The immunizing peptide was chosen to reduce cross-reactivity of AB5038 with beta-synuclein to a minimum. Immunohistochemical and Western blot analysis of human brain indicates a high level of specificity.

Immunogen

Human alpha-synuclein residues 111-131 coupled to KLH. The peptide sequence is N-GILEDMPVDPDNEAYEMPSEEC-C. This peptide is available for use in blocking studies (Cat. No. AG239).

Application

Research Category
Neuroscience
Research Sub Category
Neurodegenerative Diseases
This Anti-Synuclein Antibody, α is validated for use in IH(P), WB for the detection of Synuclein.
Western blot: 1:1000-1:2000

Immunohistochemistry: 1:1000-1:2000 on paraffin sections, 1:4000-1:12,000 on frozen sections..

Optimal working dilutions must be determined by end user.

Target description

14-19 kDa

Linkage

Replaces: 04-1053

Physical form

Affinity Purified immunoglobulin. Lyophilized, no preservatives. Reconstitute with 20 μL of sterile distilled water. Centrifuge to remove any residue.
ImmunoAffinity Purified

Storage and Stability

Maintain at -20 in undiluted aliquots for up to 12 months after date of receipt. After reconstitution maintain at -20°C in undiluted aliquots for up to 6 months. Avoid repeated freeze/thaw cycles. Glycerol (1:1) can be added for additional stability.

Analysis Note

Control
Brain tissue

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


  • Certificates of Analysis (COA)

    Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    Juan C Vizcarra et al.
    Free neuropathology, 4 (2023-06-22)
    The collection of post-mortem brain tissue has been a core function of the Alzheimer Disease Research Center's (ADRCs) network located within the United States since its inception. Individual brain banks and centers follow detailed protocols to record, store, and manage
    Christopher Gibbons et al.
    Neurology, 100(15), e1529-e1539 (2023-01-20)
    Multiple system atrophy (MSA) is a progressive neurodegenerative disorder caused by the abnormal accumulation of α-synuclein in the nervous system. Clinical features include autonomic and motor dysfunction, which overlap with those of Parkinson disease (PD), particularly at early disease stages.
    Dominique Bétemps et al.
    Acta neuropathologica communications, 2, 29-29 (2014-03-15)
    The accumulation of misfolded proteins appears as a fundamental pathogenic process in human neurodegenerative diseases. In the case of synucleinopathies such as Parkinson's disease (PD) or dementia with Lewy bodies (DLB), the intraneuronal deposition of aggregated alpha-synuclein (αS) is a
    Michael Helwig et al.
    Brain : a journal of neurology, 139(Pt 3), 856-870 (2016-01-01)
    Aggregation and neuron-to-neuron transmission are attributes of α-synuclein relevant to its pathogenetic role in human synucleinopathies such as Parkinson's disease. Intraparenchymal injections of fibrillar α-synuclein trigger widespread propagation of amyloidogenic protein species via mechanisms that require expression of endogenous α-synuclein
    Raffaella Rusconi et al.
    Aging cell, 17(2) (2018-02-01)
    Increased expression of α-synuclein can initiate its long-distance brain transfer, representing a potential mechanism for pathology spreading in age-related synucleinopathies, such as Parkinson's disease. In this study, the effects of overexpression-induced α-synuclein transfer were assessed over a 1-year period after

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service